Tests LBL-024 alone or with toripalimab in advanced melanoma
Tests LBL-024 alone or with toripalimab in adults with advanced melanoma.
Plain-language title generated from the registry record
Registry title: A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
Key facts
- Where
- Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanjing, Nanning, Shanghai, Taiyuan, Tianjin, Wuhan, and Xi'an, ChinaSee the 16 sites
- Phase
- Phase 1/2
Where in China
- Beijing GoBroad HospitalBeijing, ChinaNot yet recruiting
- The First Hospital of Jilin UniversityChangchun, ChinaTaking people
- West China Hospital of Sichuan UniversityChengdu, ChinaTaking people
- Fujian Cancer HospitalFuzhou, ChinaTaking people
- Dermatology Hospital of Southern Medical UniversityGuangzhou, ChinaNot yet recruiting
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
- Zhejiang Cancer HospitalHangzhou, ChinaNot yet recruiting
- Shandong Cancer HospitalJinan, ChinaTaking people
- Yunnan Cancer HospitalKunming, ChinaTaking people
- Nanjing Drum Tower hospitalNanjing, ChinaTaking people
- Guangxi Medical University Cancer HospitalNanning, ChinaTaking people
- Fudan University Shanghai Cancer CenterShanghai, ChinaNot yet recruiting
- Shanxi Bethune HospitalTaiyuan, ChinaTaking people
- Tianjin Medical University Cancer Institute & HospitalTianjin, ChinaNot yet recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
- The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing Leads Biolabs Co.,Ltd
- Trial code
- NCT07099430
- Record updated
- 21 October 2026
- Original description
This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy or combination with toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.Read full original descriptionShow less
An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy or combination with toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.
Inclusion: Agree to follow the trial treatment regimen, visit schedule,laboratory test, and comply with other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent; At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited; The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1; The expected survival time is at least 12 weeks; According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours）, the subjects enrolled have at least one measurable neoplasm lesion; Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.
Exclusion: Subjects who received live vaccination within 4 weeks before the first dose or were planned to receive live vaccination during the study period and 4 weeks after the dose; Major surgery or other treatment or diagnosis that has a significant impact on the participant within 4 weeks before the first dose; Patients with active, or who have had and have the possibility of recurrence of autoimmune diseases; History of severe cardiovascular and cerebrovascular disorder; Active infectious disease; History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction; The investigator believes that the participant has other conditions that may affect compliance or are not suitable for participating in this study; Women during pregnancy or lactation.